A new study has shown that the ‘Quad’ single-tablet regimen has antiviral efficacy at least as good as comparison regimens and is associated with fewer adverse events than Atripla or ritonavir-boosted atazanavir (Reyataz). The new four-in-one ‘Quad’ coformulation contains the next-generation integrase inhibitor elvitegravir, the novel boosting agent cobicistat, and tenofovir and FTC (the latter two are the drugs in Truvada). It was approved by the US Food and Drug Administration in August 2012 for adults starting HIV treatment for the first time and is marketed under the brand name Stribild in the US.

The full article can be read here.

I love it. My whole family takes it. Cheap cialis in uk? More information regarding generic medications can be found at this link. We can give you a 100% guarantee for it!